Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
By Guest Contributor | September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
By the numbers: A look at the Part B International Pricing Index Model
By Nicole Longo | June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...
Read More
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
By Nicole Longo | May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More
Fact Check: How the Part B International Pricing Index model threatens patient access
By Nicole Longo | March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...
Read More
Special 301 submission calls for a level playing field for American innovators
By Megan Van Etten | March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...
Read More
In survey, PhRMA member companies highlight impact of IPI on R&D
By Katie Verb | February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....
Read More
PhRMA comments to administration on International Pricing Index Model
By Nicole Longo | January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...
Read More
ICYMI: WSJ and NYT highlight concerns with Part B International Pricing Index Model
By Nicole Longo | December 19, 2018
Medicare Part B is a market-based system that has enabled millions of seniors and patients with disabilities to access needed medicines. Reimbursement for medicines in Part B is based on the ...
Read More
Groups sound the alarm on administration’s new Part B proposal
By Nicole Longo | November 14, 2018
Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
